Nilotinib
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
Molecules, Vol. 29, Pages 1275: Investigation of the Influence of Anti-Solvent Precipitation Parameters on the Physical Stability of Amorphous Solids
This study’s findings indicated that amorphous solids exhibited the greatest physical stability under particular conditions, namely a feeding rate of 5 mL/min, an agitation speed of 500 rpm, and an aging time of 10 min. Furthermore, the physical stability of the amorphous solids was primarily influenced by particle size and distribution, molecular interactions, microstructure, surface area, and interfacial energy. Notably, the parameters involved in the anti-solvent precipitation process, including the feeding rate of the anti-solvent, agitation speed, and aging time, exerted a significant impact on these fac...
Source: Molecules - March 13, 2024 Category: Chemistry Authors: Zunhua Li Zicheng Gong Bowen Zhang Asad Nawaz Tags: Article Source Type: research
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.PMID:38461040 | DOI:10.1016/j.clml.2024.02.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 9, 2024 Category: Cancer & Oncology Authors: Xiaoshuai Zhang Na Xu Yunfan Yang Hai Lin Bingcheng Liu Xin Du Xiaoli Liu Rong Liang Chunyan Chen Jian Huang Huanling Zhu Ling Pan Xiaodong Wang Guohui Li Zhuogang Liu Yanqing Zhang Zhenfang Liu Jianda Hu Chunshui Liu Fei Li Wei Yang Li Meng Yanqiu Han Li Source Type: research
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.PMID:38461040 | DOI:10.1016/j.clml.2024.02.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 9, 2024 Category: Cancer & Oncology Authors: Xiaoshuai Zhang Na Xu Yunfan Yang Hai Lin Bingcheng Liu Xin Du Xiaoli Liu Rong Liang Chunyan Chen Jian Huang Huanling Zhu Ling Pan Xiaodong Wang Guohui Li Zhuogang Liu Yanqing Zhang Zhenfang Liu Jianda Hu Chunshui Liu Fei Li Wei Yang Li Meng Yanqiu Han Li Source Type: research
Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Conclusion: This study is the first to provide insights into the characteristics, treatment patterns, and outcomes of CML patients treated with TKIs in Hungarian clinical practice between 2011 and 2019. We found slightly lower OS rates compared to other European countries, however, there was a statistically significant improvement in 4-year OS during the study period. The management of CML was in line with international guidelines and recommendations.PMID:38444749 | PMC:PMC10913892 | DOI:10.3389/pore.2024.1611497 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - March 6, 2024 Category: Pathology Authors: Peter Batar Hussain Alizadeh Gyorgy Rokszin Zsolt Abonyi-Toth Judit Demeter Source Type: research
Imatinib/nilotinib
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer
This study evaluates a quantitative approach with a score to predict the clinical usefulness of TDM for oMTTs. We identified key parameters for an oMTT's suitability for TDM from standard TDM recommendations. We gathered oMTT pharmacological data, which covered exposure variability (considering pharmacokinetic (PK) impact of food and proton pump inhibitors), technical intricacy (PK linearity and active metabolites), efficacy (exposure-response relationship), and safety (maximum tolerated dose, and exposure-safety relationship). To assess the validity and the relevance of the score and define relevant thresholds, we evaluat...
Source: Clinical Pharmacology and Therapeutics - February 23, 2024 Category: Drugs & Pharmacology Authors: Arthur G éraud David Combarel Christian Funck-Brentano Quentin Beaulieu No ël Zahr Sophie Broutin Jean-Philippe Spano Christophe Massard Benjamin Besse Paul Gougis Source Type: research
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
CONCLUSIONS: The results of this study demonstrated that AE signals differ among the five BCR-ABL1 TKIs. Furthermore, each BCR-ABL1 TKI displayed several new signals. These findings provide valuable information for clinicians aiming to reduce the risk of AEs during BCR-ABL1 TKI treatment.PMID:38395895 | PMC:PMC10885429 | DOI:10.1186/s40360-024-00741-x (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 23, 2024 Category: Drugs & Pharmacology Authors: Dehua Zhao Xiaoqing Long Jisheng Wang Source Type: research
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer
This study evaluates a quantitative approach with a score to predict the clinical usefulness of TDM for oMTTs. We identified key parameters for an oMTT's suitability for TDM from standard TDM recommendations. We gathered oMTT pharmacological data, which covered exposure variability (considering pharmacokinetic (PK) impact of food and proton pump inhibitors), technical intricacy (PK linearity and active metabolites), efficacy (exposure-response relationship), and safety (maximum tolerated dose, and exposure-safety relationship). To assess the validity and the relevance of the score and define relevant thresholds, we evaluat...
Source: Clinical Pharmacology and Therapeutics - February 23, 2024 Category: Drugs & Pharmacology Authors: Arthur G éraud David Combarel Christian Funck-Brentano Quentin Beaulieu No ël Zahr Sophie Broutin Jean-Philippe Spano Christophe Massard Benjamin Besse Paul Gougis Source Type: research
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
CONCLUSIONS: The results of this study demonstrated that AE signals differ among the five BCR-ABL1 TKIs. Furthermore, each BCR-ABL1 TKI displayed several new signals. These findings provide valuable information for clinicians aiming to reduce the risk of AEs during BCR-ABL1 TKI treatment.PMID:38395895 | PMC:PMC10885429 | DOI:10.1186/s40360-024-00741-x (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 23, 2024 Category: Drugs & Pharmacology Authors: Dehua Zhao Xiaoqing Long Jisheng Wang Source Type: research
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer
This study evaluates a quantitative approach with a score to predict the clinical usefulness of TDM for oMTTs. We identified key parameters for an oMTT's suitability for TDM from standard TDM recommendations. We gathered oMTT pharmacological data, which covered exposure variability (considering pharmacokinetic (PK) impact of food and proton pump inhibitors), technical intricacy (PK linearity and active metabolites), efficacy (exposure-response relationship), and safety (maximum tolerated dose, and exposure-safety relationship). To assess the validity and the relevance of the score and define relevant thresholds, we evaluat...
Source: Clinical Pharmacology and Therapeutics - February 23, 2024 Category: Drugs & Pharmacology Authors: Arthur G éraud David Combarel Christian Funck-Brentano Quentin Beaulieu No ël Zahr Sophie Broutin Jean-Philippe Spano Christophe Massard Benjamin Besse Paul Gougis Source Type: research
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
CONCLUSIONS: The results of this study demonstrated that AE signals differ among the five BCR-ABL1 TKIs. Furthermore, each BCR-ABL1 TKI displayed several new signals. These findings provide valuable information for clinicians aiming to reduce the risk of AEs during BCR-ABL1 TKI treatment.PMID:38395895 | PMC:PMC10885429 | DOI:10.1186/s40360-024-00741-x (Source: BMC Pharmacology and Toxicology)
Source: BMC Pharmacology and Toxicology - February 23, 2024 Category: Drugs & Pharmacology Authors: Dehua Zhao Xiaoqing Long Jisheng Wang Source Type: research
Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma
ConclusionOur findings revealed that a novel mechanism that nilotinib in combination with sunitinib overcomes sunitinib resistance in RCC. Therefore, this novel rational combination regimen provides a promising therapeutic avenue for metastatic RCC and rationale for evaluating this combination clinically. (Source: Cellular Oncology)
Source: Cellular Oncology - February 23, 2024 Category: Cancer & Oncology Source Type: research
